Company Overview

Pharmadrug Inc. is a publicly traded life sciences company focused on the development, commercialization, and distribution of controlled substances for medical and pharmaceutical use. The company operates primarily at the intersection of the pharmaceutical, medical cannabis, and psychedelic-assisted therapeutics industries, with an emphasis on regulatory-compliant markets. Its business model centers on acquiring or developing assets that can operate legally within tightly regulated frameworks, particularly in Europe and North America.

The company’s evolution reflects a strategic pivot from early-stage cannabis distribution toward specialty pharmaceutical and psychedelic-related opportunities. Pharmadrug traces its origins to cannabis-focused operations in Canada before restructuring and expanding into European pharmaceutical distribution and controlled-substance research initiatives. This transition was driven by regulatory developments and the company’s assessment that pharmaceutical-grade distribution and emerging psychedelic therapies offer more sustainable long-term growth than commoditized cannabis markets.

Business Operations

Pharmadrug’s operations are organized around pharmaceutical distribution and controlled-substance development through wholly owned subsidiaries. A core operating entity is Pharmadrug Production GmbH, which holds regulatory approvals to distribute pharmaceutical products, including medical cannabis, to pharmacies and healthcare providers in Germany. Revenue generation is primarily derived from wholesale pharmaceutical distribution rather than direct-to-consumer sales.

In addition to pharmaceutical distribution, the company has invested in early-stage psychedelic truffle research and commercialization activities in jurisdictions where such products are legal. These operations are conducted through European subsidiaries, including Sairiyo Therapeutics, which focuses on research, intellectual property development, and potential medical applications of psilocybin-containing truffles. Data inconclusive based on available public sources regarding the scale and revenue contribution of psychedelic-related operations compared with pharmaceutical distribution.

Strategic Position & Investments

Pharmadrug’s strategic direction emphasizes regulatory-first market entry, prioritizing jurisdictions with established legal frameworks for controlled substances. Growth initiatives include expanding pharmaceutical distribution relationships in Europe, securing additional product supply agreements, and selectively investing in psychedelic-related intellectual property that could support future clinical or therapeutic applications.

The company has pursued acquisitions and asset purchases rather than large-scale mergers, targeting niche operators with existing licenses or regulatory approvals. Notable investments include its ownership and continued funding of Sairiyo Therapeutics, positioned as a long-term option on the emerging psychedelic therapeutics sector. While management has publicly stated an interest in expanding into additional European markets, data inconclusive based on available public sources regarding the timing and certainty of these expansions.

Geographic Footprint

Pharmadrug maintains its corporate presence in Canada, while its primary operating footprint is in Germany and other parts of Europe. Germany represents the company’s most significant market due to its established medical cannabis and pharmaceutical distribution infrastructure and reimbursement environment.

Beyond Europe, Pharmadrug retains a public-company presence in North America through its listings and investor base, but it does not currently report material operating revenues from the United States. International influence is primarily investment- and IP-based rather than through large-scale physical operations outside Europe.

Leadership & Governance

Pharmadrug is led by an executive team with experience in public markets, regulated pharmaceuticals, and early-stage life sciences investing. Leadership has emphasized disciplined capital allocation, regulatory compliance, and the pursuit of assets with defined legal pathways rather than speculative drug development.

Key executives include:

• Daniel Cohen – Chief Executive Officer
• Daniel Gallucci – Chief Financial Officer
• Fadi Yassine – Director
• Frank J. Carnevale – Director

Management’s stated strategic vision focuses on building a diversified portfolio of compliant pharmaceutical and controlled-substance assets, leveraging regulatory approvals as a competitive barrier while maintaining flexibility to adapt to evolving drug policy frameworks.